Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Vaxcyte, Inc.

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Appoints John Furey to Board of Directors
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Announces Pricing of $750 Million Public Offering
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Appoints Whitney Jones as Chief People Officer
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Appoints Jacks Lee to Board of Directors
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX STRO
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.